Impact of Generic Liraglutide Launch on Weight ...

By João L. Carapinha

September 3, 2025

Teva’s recent announcement of the U.S. Food and Drug Administration (FDA) approval and the generic liraglutide launch marks a significant development in the weight-loss therapeutics market. The introduction of the first generic version of Saxenda ...
Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidiscipl...
Mounjaro Price Increase UK: Impacts on Access and Health Economics
Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflamma...
AMALFI Trial: How Patch-Based ECG Monitoring Could Transform Remote Atrial Fi...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
FDA Guidance on Overall Survival Assessment in Oncology Trials
Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditiona...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required